Avidity Biosciences (RNA) said Wednesday it plans to file a biologics license application for delpacibart zotadirsen, or del-zota, for patients with Duchenne muscular dystrophy mutations amenable to exon 44 skipping for year end.
The US Food and Drug Administration confirmed the accelerated approval path is available for del-zota and that the clinical data package from the EXPLORE44 program could support a BLA filing, the company said.
"We look forward to an exciting year ahead as we prepare to become a commercial organization," said Chief Executive Officer Sarah Boyce.
Avidity also said it is on track to complete enrollment in del-desiran HARBOR Phase 3 and potential registrational del-brax biomarker cohort as well as initiate global pivotal trial for del-brax by mid-2025.
The company said Eric Mosbrooker expanded his role to chief commercial officer to lead its multiple product launches. It also said Charles Calderaro III has joined the firm as chief technical officer, and Kat Lange as chief business officer.
Price: 30.83, Change: +0.04, Percent Change: +0.13
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。
沒有相關數據
如果下載按鈕點擊無跳轉,請點擊右上角菜單選擇 “在瀏覽器打開”